The contract adds predictable recurring revenue but is too small in absolute unit volume (77k/year) to materially move the needle for a $14M market cap company. Monitor future 10-Q for actual revenue contribution from this agreement and any additional contract wins that could scale the manufacturing segment.
Price Chart
Executive Summary
Cosmos Health subsidiary Cana Laboratories inaugurated a new capsule production line and secured a five-year contract manufacturing agreement with Provident Pharmaceuticals to produce 385,000 units of CERTORUN® (sertraline HCl) at 77,000 units annually. The deal builds on an existing relationship and adds recurring, high-margin revenue, but financial terms were not disclosed and the absolute production volume is modest relative to the company's scale.
Key Facts
- Cana Laboratories secured a five-year contract manufacturing agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN® (sertraline HCl) at 77,000 units per year.
- Production will use Cana's newly installed ACG capsule-filling line.
- This agreement follows prior contracts for DE3-SOLE®, MIOREL®, CALCIFOLIN®, and DEXA-DOSE®.
- No financial terms (revenue, margin, or upfront payment) were disclosed.
Financial Impact
Undisclosed — no revenue, margin, or dollar value provided for the contract.
Risk Factors
- Financial terms undisclosed — actual revenue impact may be negligible.
- Dependence on single counterparty (Provident) for this contract.
- Execution risk on new production line ramp-up.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2360 (−6.72%) |
Oct 16, 2026 11d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2360 (−27.38%) |
Oct 9, 2026 18d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2360 (−32.49%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2360 (+11.28%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2360 (−22.28%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2360 (+2.48%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2360 (+0.51%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2360 (−15.92%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2360 (−15.26%) |
Jul 14, 2026 15w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2360 (−23.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers